IL259479B - Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor - Google Patents

Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Info

Publication number
IL259479B
IL259479B IL259479A IL25947918A IL259479B IL 259479 B IL259479 B IL 259479B IL 259479 A IL259479 A IL 259479A IL 25947918 A IL25947918 A IL 25947918A IL 259479 B IL259479 B IL 259479B
Authority
IL
Israel
Prior art keywords
fucose
deoxy
fluoro
combination
cancer treatment
Prior art date
Application number
IL259479A
Other languages
English (en)
Hebrew (he)
Other versions
IL259479A (en
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of IL259479A publication Critical patent/IL259479A/en
Publication of IL259479B publication Critical patent/IL259479B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL259479A 2015-12-04 2018-05-21 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor IL259479B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US201662321857P 2016-04-13 2016-04-13
PCT/US2016/064783 WO2017096274A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Publications (2)

Publication Number Publication Date
IL259479A IL259479A (en) 2018-07-31
IL259479B true IL259479B (en) 2022-03-01

Family

ID=58797961

Family Applications (1)

Application Number Title Priority Date Filing Date
IL259479A IL259479B (en) 2015-12-04 2018-05-21 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Country Status (13)

Country Link
US (1) US20180353524A1 (https=)
EP (1) EP3383404A4 (https=)
JP (1) JP6906520B2 (https=)
KR (1) KR20180086233A (https=)
CN (1) CN108289903B (https=)
AU (1) AU2016362993A1 (https=)
BR (1) BR112018011261A2 (https=)
CA (1) CA3005997A1 (https=)
EA (1) EA201891340A1 (https=)
IL (1) IL259479B (https=)
MX (1) MX385283B (https=)
SG (2) SG10202005298RA (https=)
WO (1) WO2017096274A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2608796T3 (en) 2010-08-05 2019-03-18 Seattle Genetics Inc Inhibition of protein fucosylation in vivo using fucose analogues
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
JP7245177B2 (ja) * 2017-06-07 2023-03-23 シージェン インコーポレイテッド 低減した表面フコシル化を有するｔ細胞、及びそれを作製及び使用する方法
WO2019075449A1 (en) * 2017-10-13 2019-04-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. FUCOSYLATION AND IMMUNOSURVEILLANCE OF MELANOMA
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
SG11202106481SA (en) * 2018-12-19 2021-07-29 Seagen Inc Controlled fucosylation of antibodies
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN111973749B (zh) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 一种抗肿瘤免疫治疗的药物组合物
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (zh) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于特定型三阴乳腺癌免疫治疗的组合物
WO2022236017A1 (en) * 2021-05-06 2022-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
CN115466297B (zh) * 2022-08-25 2023-07-07 青岛农业大学 L-岩藻糖的应用以及动物饲料
WO2024077106A2 (en) * 2022-10-04 2024-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2608796T3 (en) * 2010-08-05 2019-03-18 Seattle Genetics Inc Inhibition of protein fucosylation in vivo using fucose analogues
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물

Also Published As

Publication number Publication date
BR112018011261A2 (pt) 2018-11-21
EP3383404A4 (en) 2019-07-31
EP3383404A1 (en) 2018-10-10
WO2017096274A1 (en) 2017-06-08
SG11201804263PA (en) 2018-06-28
JP2019501145A (ja) 2019-01-17
US20180353524A1 (en) 2018-12-13
JP6906520B2 (ja) 2021-07-21
CN108289903B (zh) 2021-08-03
MX385283B (es) 2025-03-18
SG10202005298RA (en) 2020-07-29
AU2016362993A1 (en) 2018-07-12
MX2018006674A (es) 2018-11-09
KR20180086233A (ko) 2018-07-30
CN108289903A (zh) 2018-07-17
CA3005997A1 (en) 2017-06-08
EA201891340A1 (ru) 2018-11-30
IL259479A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
IL259162B (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SI3283527T1 (sl) Kombinirana terapija proti raku
HUE070659T2 (hu) KDM1A inhibitor és annak felhasználása terápiában
PL2976106T3 (pl) Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor
DK3298845T3 (da) Programmering i licensunderstøttet tilgang
SI3371165T1 (sl) Zaviralec BTK za uporabo pri zdravljenju raka
PT3197456T (pt) Tratamentos de cancro
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3230318T3 (da) Immune checkpoint-inhibitor-kombinationer
HUE040167T2 (hu) Rákkezelés
PL3463436T3 (pl) Szczepionka w połączeniu z inhibitorem immunologicznego punktu kontrolnego do stosowania w leczeniu nowotworów
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
IL255560B (en) Macropinocytosis in cancer
PL3071192T3 (pl) Związek kurkufenol do zastosowania w leczeniu nowotworu
DK3380468T3 (da) Bis-pyridazinforbindelser og anvendelse heraf i behandling af cancer
FI20145740A7 (fi) Sovitelma puomistossa
DK2979704T3 (da) Desmoglein-3-peptider i pemphigus vulgaris
DK3164195T3 (da) Glutaminaseinhibitorterapi
BR302014001187S1 (pt) Configuração aplicada em estojo porta-objetos
HK1262072A1 (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
FI10846U1 (fi) Sovitelma saunan yhteydessä
TH1501006324A (th) การบำบัดมะเร็งด้วยไดไฮโดรพิแรซิโน-พิแรซีน
BR302014001882S1 (pt) Configuração aplicada em solado